Clarity Pharmaceuticals (ASX:CU6) said that its copper-64-SAR-bisPSMA diagnostic candidate identified a "statistically significant" greater number of lesions per participant than standard-of-care gallium-68-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in the Co-PSMA investigator-initiated trial, according to a Monday Australian bourse filing.

The phase two trial evaluated the performance of Clarity's diagnostic candidate, copper-64-SAR-bisPSMA, in comparison with gallium-68-PSMA-11 in 50 prostate cancer patients with biochemical recurrence of prostate cancer following radical prostatectomy, who were candidates for curative salvage therapy.

The mean per-patient lesion was 1.3 for copper-64-SAR-bisPSMA PET/CT, compared with 0.5 for gallium-68-PSMA-11, with a difference of 0.8. In total, gallium-68-PSMA-11 identified 24 lesions across all participants, while copper-64-SAR-bisPSMA next-day imaging detected 63 lesions.

At a per-patient level, gallium-68-PSMA-11 identified 36% of trial participants as having a positive scan, while copper-64-SAR-bisPSMA next-day imaging detected prostate cancer in 78% of cases.

The data outlining results from the Co-PSMA trial will be presented at the EAU Congress 2026 in London.

Clarity Pharmaceuticals' shares jumped nearly 18% in recent trading on Monday.